Dr Mark David Goodman, PHD FPPR | |
125 W. 2nd Avenue, Suite E, Hutchinson, KS 67501-5300 | |
(620) 663-4802 | |
(620) 663-9867 |
Full Name | Dr Mark David Goodman |
---|---|
Gender | Male |
Speciality | Clinical Psychologist |
Experience | 49 Years |
Location | 125 W. 2nd Avenue, Hutchinson, Kansas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1629039854 | NPI | - | NPPES |
100237680A | Medicaid | KS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC0700X | Psychologist - Clinical | 374 (Kansas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Mark David Goodman, PHD FPPR Po Box 1221, Hutchinson, KS 67504-1221 Ph: (620) 663-4802 | Dr Mark David Goodman, PHD FPPR 125 W. 2nd Avenue, Suite E, Hutchinson, KS 67501-5300 Ph: (620) 663-4802 |
News Archive
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.
Case Western Reserve University School of Medicine's Gunnur Karakurt, PhD has been awarded a four-year, $1.3 million grant from the National Institutes of Health to identify effective treatments for intimate partner violence, and to develop a decision-making tool for care providers.
Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.
Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors.
› Verified 7 days ago
Thomas Brad Chapin, LCP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1715 E 23rd Ave, Hutchinson, KS 67502 Phone: 620-665-2240 Fax: 620-665-2276 | |
Tapatha K Strickler, TLMLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1715 E 23rd Ave, Hutchinson, KS 67502 Phone: 620-665-2240 Fax: 620-665-2276 | |
Jennifer R Schreiner, LCP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1600 N Lorraine St, Suite 202, Hutchinson, KS 67501 Phone: 620-663-7595 Fax: 620-728-2036 | |
Julie W Allen, LCP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1600 N Lorraine St Ste 202, Hutchinson, KS 67501 Phone: 620-663-7595 Fax: 620-513-5098 | |
Ms. Sheri Yvonne Sherrill, LMLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1600 N Lorraine St Ste 202, Hutchinson, KS 67501 Phone: 620-663-7595 Fax: 620-513-5098 | |
Elizabeth Ann Mansel, LCP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1602 N Main St, Hutchinson, KS 67501 Phone: 620-662-7809 | |
Delmer H Thibault, LMLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1715 E 23rd Ave, Hutchinson, KS 67502 Phone: 620-665-2240 Fax: 620-665-2276 |